Bacthera AG, IQVIA AG, PharmaBiome AG
|Date:||April 25, 2023|
Microbiome – the emergence of a new treatment paradigm across a wide range of disease areas
The microbiome is a rapidly advancing field. After a decade of research, the first microbiome-based products received market approval, opening up new commercial opportunities. This panel is designed as educational piece for a broad audience discussing true drug development in the field. Switzerland is a global leader in microbiome innovation, with world-class research institutions and companies driving progress in the field to develop new treatments.
Tomas de Wouters, PharmaBiome
Gemma Henderson, Bacthera
Stefan Lutzmayer, IQVIA
Kristin Wannerberger, Ferring Pharmaceuticals
Simon Ittig, T3 Pharma
Bacthera, CDMO for LBPs, offers innovative solutions to advance the industry, establishing a Microbiome Center of Excellence for LBP manufacturing in Switzerland.
IQVIA is a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry.
PharmaBiome has developed the world’s first true drug-development platform for targeted microbiome therapeutics.